DK0903345T3 - Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid - Google Patents

Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Info

Publication number
DK0903345T3
DK0903345T3 DK98114373T DK98114373T DK0903345T3 DK 0903345 T3 DK0903345 T3 DK 0903345T3 DK 98114373 T DK98114373 T DK 98114373T DK 98114373 T DK98114373 T DK 98114373T DK 0903345 T3 DK0903345 T3 DK 0903345T3
Authority
DK
Denmark
Prior art keywords
trifluoromethylphenyl
isoxazole
carboxamide
methyl
crystal form
Prior art date
Application number
DK98114373T
Other languages
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Uwe Dr Westenfelder
Erich Dr Paulus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0903345T3 publication Critical patent/DK0903345T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK98114373T 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid DK0903345T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
DK0903345T3 true DK0903345T3 (da) 2000-10-23

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Country Status (28)

Country Link
US (5) US6060494A (da)
EP (2) EP0903345B1 (da)
JP (2) JPH11124372A (da)
KR (2) KR100544041B1 (da)
CN (2) CN1089759C (da)
AR (1) AR015418A1 (da)
AT (2) ATE196764T1 (da)
AU (1) AU752764B2 (da)
BR (1) BR9806568A (da)
CA (1) CA2245267C (da)
CZ (3) CZ292943B6 (da)
DE (2) DE59801792D1 (da)
DK (2) DK0987256T3 (da)
ES (2) ES2166205T3 (da)
GR (1) GR3034814T3 (da)
HK (2) HK1017681A1 (da)
HU (2) HU229232B1 (da)
ID (1) ID20667A (da)
IL (1) IL125671A (da)
NO (1) NO310871B1 (da)
NZ (1) NZ331270A (da)
PL (1) PL192126B1 (da)
PT (2) PT987256E (da)
RU (1) RU2224753C2 (da)
SK (2) SK282641B6 (da)
TR (2) TR199801513A2 (da)
TW (1) TW593288B (da)
UA (1) UA54411C2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166205T3 (es) * 1997-08-08 2002-04-01 Aventis Pharma Gmbh Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
IL149792A0 (en) * 1999-12-16 2002-11-10 Teva Pharma Novel processes for making and a new crystalline form of leflunomide
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
WO2002040458A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
EP1507531B1 (en) * 2003-03-12 2007-01-24 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
US8222422B2 (en) * 2008-03-10 2012-07-17 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
SI2477611T1 (sl) 2009-09-18 2017-07-31 Sanofi Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
BR9008022A (pt) * 1990-05-18 1993-04-06 Hoechst Ag Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (da) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
KR100365064B1 (ko) * 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ES2166205T3 (es) * 1997-08-08 2002-04-01 Aventis Pharma Gmbh Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
IL149792A0 (en) * 1999-12-16 2002-11-10 Teva Pharma Novel processes for making and a new crystalline form of leflunomide
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
HK1017681A1 (en) 1999-11-26
US20030166945A1 (en) 2003-09-04
CZ246898A3 (cs) 1999-02-17
SK285216B6 (sk) 2006-09-07
PL327901A1 (en) 1999-02-15
TR200600582A1 (tr) 2006-08-21
CN1208034A (zh) 1999-02-17
AU7887098A (en) 1999-02-18
US20030027851A1 (en) 2003-02-06
TW593288B (en) 2004-06-21
JPH11124372A (ja) 1999-05-11
KR20050077498A (ko) 2005-08-02
ES2166205T3 (es) 2002-04-01
CA2245267A1 (en) 1999-02-08
NO983632L (no) 1999-02-09
IL125671A0 (en) 1999-04-11
KR100588254B1 (ko) 2006-06-12
HUP9801844A2 (hu) 2000-02-28
EP0903345A1 (de) 1999-03-24
HU0700190D0 (en) 2007-05-02
EP0987256B1 (de) 2001-10-17
KR100544041B1 (ko) 2006-09-18
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
US6221891B1 (en) 2001-04-24
CN1089759C (zh) 2002-08-28
ATE196764T1 (de) 2000-10-15
UA54411C2 (uk) 2003-03-17
AU752764B2 (en) 2002-09-26
IL125671A (en) 2002-11-10
CZ292943B6 (cs) 2004-01-14
CZ301514B6 (cs) 2010-03-31
EP0903345B1 (de) 2000-10-04
DE59800287D1 (de) 2000-11-09
PL192126B1 (pl) 2006-09-29
NO983632D0 (no) 1998-08-07
HU9801844D0 (en) 1998-10-28
ATE207065T1 (de) 2001-11-15
ID20667A (id) 1999-02-11
US6995272B2 (en) 2006-02-07
SK105898A3 (en) 1999-02-11
BR9806568A (pt) 2000-05-16
SK282641B6 (sk) 2002-10-08
JP2009280604A (ja) 2009-12-03
US6900334B2 (en) 2005-05-31
HU225870B1 (en) 2007-11-28
PT903345E (pt) 2001-01-31
AR015418A1 (es) 2001-05-02
ES2150808T3 (es) 2000-12-01
HUP9801844A3 (en) 2000-04-28
CA2245267C (en) 2008-12-23
RU2224753C2 (ru) 2004-02-27
PT987256E (pt) 2002-03-28
GR3034814T3 (en) 2001-02-28
US6552202B2 (en) 2003-04-22
NO310871B1 (no) 2001-09-10
EP0987256A1 (de) 2000-03-22
DE59801792D1 (de) 2001-11-22
CN1373126A (zh) 2002-10-09
US6060494A (en) 2000-05-09
KR19990023433A (ko) 1999-03-25
HK1049481A1 (en) 2003-05-16
CN1181064C (zh) 2004-12-22
HU229232B1 (en) 2013-09-30
HK1049481B (zh) 2005-07-08
TR199801513A3 (tr) 1999-02-22
TR199801513A2 (xx) 1999-02-22
DK0987256T3 (da) 2002-02-11
CZ301426B6 (cs) 2010-02-24

Similar Documents

Publication Publication Date Title
DK0903345T3 (da) Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
DK0998473T3 (da) Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse
DK0908449T3 (da) Fremstilling af carotenoider
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
DK38293D0 (da) Fremstilling af proteiner
NO983666L (no) Krystallmodifikasjon av et farmas°ytisk middel
DK1102747T3 (da) Krystalformer af osenetant
DK0823876T3 (da) Fremstilling af poser
DE69800559T2 (de) Ferrielektrische Flüssigkristallverbindung
DE69927626D1 (de) Ausführung von Permutationen
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
DK0689577T3 (da) Anvendelse af ferroncen
DK82592D0 (da) Fremstilling af proteiner
ATE232199T1 (de) Polymorphe modifikationen von dofetilid
DE69528320T2 (de) Optische Frequenzmischanordnung
DK0859001T3 (da) Fremstilling af oxazolderivater
DK0927163T3 (da) Fremstilling af 1-butyl-4-piperidinylmethylamin
DK0882722T3 (da) Fremstilling af alpha-tocopherol
FI974508A (fi) Iskuja synnyttävä laite
IL139438A0 (en) Crystal form of n- (4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
ZA987127B (en) Crystal form of N-(4-trifuloromethylphenyl)-5-methylisoxazole-4-carboxamide
DE59813826D1 (de) Optisch-parametrischer Oszillator
KR970019983U (ko) 크리스탈 진동자의 공동 사용회로